Current therapy and future directions in biliary tract malignancies

Area of Science:

• Oncology
• Gastroenterology
• Surgical Oncology

Background:

• Biliary tract cancers (gallbladder cancer, cholangiocarcinoma) are rare with poor prognoses.
• Gallbladder cancer is linked to cholelithiasis; cholangiocarcinoma often lacks identifiable risk factors.
• Surgical resection is curative but often not feasible at diagnosis and associated with high recurrence rates.

Purpose of the Study:

• To review current understanding of biliary tract cancers, including risk factors and treatment strategies.
• To highlight the limitations of existing therapies and the need for novel approaches.
• To emphasize the importance of ongoing clinical trials for advanced biliary tract cancers.

Main Methods:

• Review of existing literature on biliary tract cancers.
• Analysis of current treatment standards, including surgery, adjuvant therapies, and chemotherapy.
• Discussion of ongoing and planned clinical trials.

Main Results:

• Surgical resection is the cornerstone of curative treatment but faces challenges with recurrence and resectability.
• Adjuvant therapies (radiation, embolization) show modest success; prospective data are limited.
• Gemcitabine plus cisplatin is the standard chemotherapy for advanced disease, offering survival and quality-of-life benefits, but resistance eventually develops.

Conclusions:

• Optimizing adjuvant therapies and clarifying their role post-resection requires further investigation.
• Development of novel agents is essential as all patients eventually progress on current chemotherapy.
• Clinical trials are critical for advancing treatment options and improving survival for biliary tract cancer patients.